Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS).

Farooq S, Nazar Z, Irfan M, Akhter J, Gul E, Irfan U, Naeem F.

Br J Psychiatry. 2011 Dec;199(6):467-72. doi: 10.1192/bjp.bp.110.085340.

2.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

3.

An exploratory, randomized controlled trial of adherence therapy for people with schizophrenia.

Anderson KH, Ford S, Robson D, Cassis J, Rodrigues C, Gray R.

Int J Ment Health Nurs. 2010 Oct;19(5):340-9. doi: 10.1111/j.1447-0349.2010.00681.x.

PMID:
20887608
4.

An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand.

Maneesakorn S, Robson D, Gournay K, Gray R.

J Clin Nurs. 2007 Jul;16(7):1302-12.

PMID:
17584349
5.

[Therapeutic alliance, a stake in schizophrenia].

Charpentier A, Goudemand M, Thomas P.

Encephale. 2009 Feb;35(1):80-9. doi: 10.1016/j.encep.2007.12.009. Epub 2008 May 19. Review. French.

PMID:
19250998
6.

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.

Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW.

J Clin Psychiatry. 2006 Mar;67(3):453-60.

PMID:
16649833
7.

Treatment adherence therapy in people with psychotic disorders: randomised controlled trial.

Staring AB, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengeveld MW, Loonen AJ, Mulder CL.

Br J Psychiatry. 2010 Dec;197(6):448-55. doi: 10.1192/bjp.bp.110.077289.

8.

The role of the family and improvement in treatment maintenance, adherence, and outcome for schizophrenia.

Glick ID, Stekoll AH, Hays S.

J Clin Psychopharmacol. 2011 Feb;31(1):82-5. doi: 10.1097/JCP.0b013e31820597fa.

PMID:
21192148
9.

A pilot study of barriers to medication adherence in schizophrenia.

Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P, Sullivan G.

J Clin Psychiatry. 2004 Feb;65(2):211-6.

PMID:
15003075
10.

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.

J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.

PMID:
19906343
11.

[Relationships between insight and medication adherence in subjects with psychosis].

Droulout T, Liraud F, Verdoux H.

Encephale. 2003 Sep-Oct;29(5):430-7. French.

PMID:
14615692
12.

Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.

Rosenheck RA, Krystal JH, Lew R, Barnett PG, Thwin SS, Fiore L, Valley D, Huang GD, Neal C, Vertrees JE, Liang MH; CSP 555 Research Group.

Clin Trials. 2011 Apr;8(2):196-204. doi: 10.1177/1740774510392931. Epub 2011 Jan 26.

PMID:
21270143
13.

How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.

Beck EM, Cavelti M, Wirtz M, Kossowsky J, Vauth R.

Psychiatry Res. 2011 May 15;187(1-2):55-61. doi: 10.1016/j.psychres.2010.10.012. Epub 2010 Nov 12.

PMID:
21074860
14.

A program for relapse prevention in schizophrenia: a controlled study.

Herz MI, Lamberti JS, Mintz J, Scott R, O'Dell SP, McCartan L, Nix G.

Arch Gen Psychiatry. 2000 Mar;57(3):277-83.

PMID:
10711914
15.

Improving treatment adherence in patients with schizophrenia.

Kane JM.

J Clin Psychiatry. 2011 Sep;72(9):e28. doi: 10.4088/JCP.9101tx2c.

16.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
17.

Novelty seeking and medication adherence in patients with schizophrenia.

Aukst Margetić B, Jakovljević M, Ivanec D, Tošić G, Margetić B.

Psychiatry Res. 2011 Mar 30;186(1):141-3. doi: 10.1016/j.psychres.2010.06.013. Epub 2010 Jul 13.

PMID:
20630601
18.

Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.

Barbui C, Kikkert M, Mazzi MA, Becker T, Bindman J, Schene A, Nosè M, Helm H, Thornicroft G, Tansella M.

Psychopathology. 2009;42(5):311-7. doi: 10.1159/000232973. Epub 2009 Aug 11.

PMID:
19672133
19.

Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.

Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A.

Curr Med Res Opin. 2010 Mar;26(3):501-9. doi: 10.1185/03007990903488670.

PMID:
20014981
20.

Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection.

Chang CL, Tzeng DS, Lung FW.

Psychiatry Res. 2010 Nov 30;180(1):16-9. doi: 10.1016/j.psychres.2009.11.005. Epub 2010 May 20.

PMID:
20488552

Supplemental Content

Support Center